"Pheochromocytoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Descriptor ID |
D010673
|
MeSH Number(s) |
C04.557.465.625.650.700.725 C04.557.580.625.650.700.725
|
Concept/Terms |
Pheochromocytoma, Extra-Adrenal- Pheochromocytoma, Extra-Adrenal
- Extra-Adrenal Pheochromocytoma
- Extra-Adrenal Pheochromocytomas
- Pheochromocytoma, Extra Adrenal
- Pheochromocytomas, Extra-Adrenal
|
Below are MeSH descriptors whose meaning is more general than "Pheochromocytoma".
Below are MeSH descriptors whose meaning is more specific than "Pheochromocytoma".
This graph shows the total number of publications written about "Pheochromocytoma" by people in this website by year, and whether "Pheochromocytoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1999 | 1 | 0 | 1 |
2003 | 0 | 1 | 1 |
2007 | 2 | 1 | 3 |
2008 | 2 | 1 | 3 |
2009 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2011 | 2 | 0 | 2 |
2012 | 1 | 0 | 1 |
2013 | 2 | 0 | 2 |
2014 | 1 | 0 | 1 |
2017 | 2 | 0 | 2 |
2020 | 2 | 0 | 2 |
2021 | 0 | 1 | 1 |
2022 | 1 | 0 | 1 |
2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pheochromocytoma" by people in Profiles.
-
Update on Tumor Surveillance for Children with Hereditary Pheochromocytoma/Paraganglioma Syndromes. Clin Cancer Res. 2025 Aug 14; 31(16):3368-3376.
-
Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nat Commun. 2025 Mar 17; 16(1):2632.
-
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e600-e606.
-
SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior? Ann Surg Oncol. 2024 Dec; 31(13):9007-9013.
-
Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice. Mol Cell Endocrinol. 2024 Oct 01; 592:112344.
-
International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Nat Rev Endocrinol. 2024 Dec; 20(12):729-748.
-
Management of metastatic pheochromocytomas and paragangliomas: when and what. Curr Probl Cancer. 2024 Aug; 51:101116.
-
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma. Eur J Cancer. 2024 Sep; 208:114122.
-
High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2024 Jul 01; 49(7):610-620.
-
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol. 2024 May; 25(5):658-667.